Innovative therapy for hepatocellular carcinoma: Three-dimensional high-dose photon radiotherapy

Cancer Letters

Volumn 286, Issue 1, 2009, Pages 129-133

  Merle, P ^a,b,c   Mornex, F ^d   Trepo, C ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Hepatocellular carcinoma; Radiotherapy

Indexed keywords

FLOXURIDINE; PLACEBO; SORAFENIB;

CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER PARENCHYMA; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PATIENT SAFETY; PHOTON THERAPY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOFREQUENCY ABLATION; SHORT SURVEY; STEREOTACTIC RADIOSURGERY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 69049111486     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.004     Document Type: Review

References (43)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics. CA Cancer J. Clin. 55 2005 (2002) 74-108
2. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. New Engl. J. Med. 340 (1999) 745-750
3. Deuffic S., Buffat L., Poynard T., and Valleron A.J. Modeling the hepatitis C virus epidemic in France. Hepatology 29 (1999) 1596-1601
4. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139 (2003) 817-823
5. Law M.G., Dore G.J., Bath N., Thompson S., Crofts N., Dolan K., et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int. J. Epidemiol. 32 (2003) 717-724
6. Stuart K.E., Anand A.J., and Jenkins R.L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77 (1996) 2217-2222
7. Chevret S., Trinchet J.C., Mathieu D., Rached A.A., Beaugrand M., and Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol. 31 (1999) 133-141
8. Wharton J.T., Delclos L., Gallager S., and Smith J.P. Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am. J. Roentgenol. 117 (1973) 73-80
9. Lewin K., and Millis R.R. Human radiation hepatitis. A morphologic study with emphasis on the late change. Arch. Pathol. 96 (1973) 21-26
10. Lawrence T.S., Robertson J.M., Anscher M.S., Jirtle R.L., Ensminger W.D., and Fajardo L.F. Hepatic toxicity resulting from cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 31 (1995) 1237-1248
11. Hawkins M.A., and Dawson L.A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106 (2006) 1653-1663
12. Lawrence T.S., Tesser R.J., and Ten Haken R.K. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 19 (1990) 1041-1047
13. Lawrence T.S., Ten Haken R.K., Kessler M.L., Robertson J.M., Lyman J.T., Lavigne M.L., et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int. J. Radiat. Oncol. Biol. Phys. 23 (1992) 781-788
14. Nagasue N., Kohno H., Chang Y.C., Taniura H., Yamanoi A., Uchida M., et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann. Surg. 217 (1993) 375-384
15. Izumi R., et al. Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20 (1994) 295-301
16. Fong Y., et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann. Surg. 229 (1999) 790-799
17. Kotoh K., Sakai H., Sakamoto S., Nakayama S., Satoh M., Morotomi I., et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am. J. Gastroenterol. 89 (1994) 194-198
18. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl. J. Med. 334 (1996) 693-699
19. Curley S.A., Izzo F., Ellis L.M., Nicolas Vauthey J., and Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann. Surg. 232 (2000) 381-391
20. Decadt B., and Sirlwardena A. Radiofrequency ablation of liver tumors: systematic review. Lancet Oncol. 5 (2004) 550-560
21. Lau W.Y., Leung T.W., Yu S.C., and Ho S.K. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann. Surg. 237 (2003) 171-179
22. Tung-Ping P.R., et al. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg. 232 (2000) 10-24
23. Ercolani G., et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann. Surg. 237 (2003) 536-543
24. Yu A.S., et al. Management of hepatocellular carcinoma. Rev. Gastroenterol. Disord. 3 (2003) 8-24
25. Schwartz J.D., et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 3 (2002) 593-603
26. Imamura H., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38 (2003) 200-207
27. J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, J. Raoul, S. Zeuzem, et al., Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial), ASCO 2007 Annual Meeting, 2007.
28. Robertson J.M., Lawrence T.S., Dworzanin L.M., Andrews J.C., Walker S., Kessler M.L., et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J. Clin. Oncol. 11 (1993) 1286-1293
29. Dawson L.A., McGinn C.J., Normolle D., Ten Haken R.K., Walker S., Ensminger W., and Lawrence T.S. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 18 (2000) 2210-2218
30. Ben-Josef E., Normolle D., Pan C., Walker S., Tatro D., Ten Haken R.K., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 23 (2005) 8739-8747
31. Park H.C., Seong J., Han K.H., Chon C.Y., Moon Y.M., and Suh C.O. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 150-155
32. Liu M.T., Li S.H., Chu T.C., Hsieh C.Y., Wang A.Y., Chang C.H., et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn. J. Clin. Oncol. 34 (2004) 532-539
33. Kim T.H., Kim D.Y., Park J.W., Kim Y.I., Kim S.H., Park H.S., et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am. J. Clin. Oncol. 29 (2006) 568-575
34. Choi B.O., Jang H.S., Kang K.M., Lee S.W., Kang Y.N., Chai G.Y., and Choi I.B. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn. J. Clin. Oncol. 36 (2006) 154-158
35. Mornex F., Girard N., Merle P., Beziat C., Kubas A., Wautot V., et al. Tolerance and efficacy of conformal radiotherapy for hepatocellular carcinoma in the cirrhotic patient. Results of the French RTF-1 trial. Cancer Radiother. 9 (2005) 470-476
36. Mornex F., Girard N., Beziat C., Kubas A., Khodri M., Trepo C., and Merle P. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients wit small-size hepatocellular carcinoma noneligible for curative therapies - mature results of the French phase-II RTF-1 trial. Int. J. Radiat. Oncol. Biol. Phys. 66 (2006) 1152-1158
37. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
38. Seong J., Keum K.C., Han K.H., Lee D.Y., Lee J.T., Chon C.Y., et al. Combined transcathter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43 (1999) 393-397
39. Guo W.J., Yu E.X., Liu L.M., Li J., Chen Z., Lin J.H., et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J. Gastroenterol. 9 (2003) 1697-1701
40. Shim S.J., Seong J., Han K.H., Chon C.Y., Suh C.O., and Lee J.T. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 25 (2005) 1189-1196
41. Guo W.J., and Yu E.X. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Brit. J. Radiol. 73 (2000) 1091-1097
42. Wu D.H., Liu L., and Chen L.H. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J. Gastroenterol. 10 (2004) 2184-2189
43. Takeda A., Takahashi M., Kunieda E., Takeda T., Sanuki N., Koike Y., et al. Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity. Hepatol. Res. 38 (2008) 60-69